Miranda A L van Tilburg1, Olafur S Palsson2, Yehuda Ringel2, William E Whitehead2. 1. University of North Carolina, Department of Medicine, Division of Gastroenterology and Hepatology, UNC Center for Functional GI and Motility Disorders, United States. Electronic address: Tilburg@med.unc.edu. 2. University of North Carolina, Department of Medicine, Division of Gastroenterology and Hepatology, UNC Center for Functional GI and Motility Disorders, United States.
Abstract
OBJECTIVES: Ginger is one of the most commonly used herbal medicines for irritable bowel syndrome (IBS) but no data exists about its effectiveness. DESIGN: Double blind randomized controlled trial. SETTING: University of North Carolina, Chapel Hill, North Carolina, USA. INTERVENTION: Forty-five IBS patients were randomly assigned to three groups: placebo, 1g of ginger, and 2g of ginger daily for 28 days. MAIN OUTCOME MEASURES: The IBS severity scale (IBS-SS) was administered, as well as adequate relief of symptoms scale. A responder was defined as having at least 25% reduction in IBS-SS post-treatment. RESULTS: There were 57.1% responders to placebo, 46.7% to 1g and 33.3% to 2g of ginger. Adequate relief was reported by 53.3% on placebo and 53.3% in both ginger groups combined. Side effects were mild and reported by 35.7% in the placebo and 16.7% in the ginger groups. CONCLUSIONS: This double blind randomized controlled pilot study suggests ginger is well tolerated but did not perform better than placebo. Larger trials are needed before any definitive conclusions can be drawn.
RCT Entities:
OBJECTIVES:Ginger is one of the most commonly used herbal medicines for irritable bowel syndrome (IBS) but no data exists about its effectiveness. DESIGN: Double blind randomized controlled trial. SETTING: University of North Carolina, Chapel Hill, North Carolina, USA. INTERVENTION: Forty-five IBSpatients were randomly assigned to three groups: placebo, 1g of ginger, and 2g of ginger daily for 28 days. MAIN OUTCOME MEASURES: The IBS severity scale (IBS-SS) was administered, as well as adequate relief of symptoms scale. A responder was defined as having at least 25% reduction in IBS-SS post-treatment. RESULTS: There were 57.1% responders to placebo, 46.7% to 1g and 33.3% to 2g of ginger. Adequate relief was reported by 53.3% on placebo and 53.3% in both ginger groups combined. Side effects were mild and reported by 35.7% in the placebo and 16.7% in the ginger groups. CONCLUSIONS: This double blind randomized controlled pilot study suggests ginger is well tolerated but did not perform better than placebo. Larger trials are needed before any definitive conclusions can be drawn.
Authors: S M Patel; W B Stason; A Legedza; S M Ock; T J Kaptchuk; L Conboy; K Canenguez; J K Park; E Kelly; E Jacobson; C E Kerr; A J Lembo Journal: Neurogastroenterol Motil Date: 2005-06 Impact factor: 3.598
Authors: Ted J Kaptchuk; Elizabeth Friedlander; John M Kelley; M Norma Sanchez; Efi Kokkotou; Joyce P Singer; Magda Kowalczykowski; Franklin G Miller; Irving Kirsch; Anthony J Lembo Journal: PLoS One Date: 2010-12-22 Impact factor: 3.240
Authors: Miranda A L van Tilburg; Olafur S Palsson; Rona L Levy; Andrew D Feld; Marsha J Turner; Douglas A Drossman; William E Whitehead Journal: BMC Complement Altern Med Date: 2008-07-24 Impact factor: 3.659
Authors: Nguyen Hoang Anh; Sun Jo Kim; Nguyen Phuoc Long; Jung Eun Min; Young Cheol Yoon; Eun Goo Lee; Mina Kim; Tae Joon Kim; Yoon Young Yang; Eui Young Son; Sang Jun Yoon; Nguyen Co Diem; Hyung Min Kim; Sung Won Kwon Journal: Nutrients Date: 2020-01-06 Impact factor: 5.717
Authors: Hussein S Amin; Farhana Irfan; Syed I Karim; Saif M Almeshari; Khaled A Aldosari; Abdullah M Alzahrani; Adnan T Almogbel; Saad M Alfouzan; Anas A Alsaif Journal: Saudi J Gastroenterol Date: 2021 Nov-Dec Impact factor: 2.485
Authors: Rebecca N Cherry; Samra S Blanchard; Ashish Chogle; Neha R Santucci; Khyati Mehta; Alexandra C Russell Journal: Children (Basel) Date: 2022-08-22